Arias MMA, Rojas VG, Vieyra HG, Lagunas UOA, Juárez HÚ, Martínez SCR

Idioma: Español
Referencias bibliográficas: 17
Paginas: 27-33
Archivo PDF: 76.42 Kb.

FRAGMENTO

El síndrome de insuficiencia cardíaca aguda, se define como la presentación de signos y síntomas de disfunción ventricular, los cuales producen hipertensión pulmonar severa, debido a elevación de la presión de llenado del ventrículo izquierdo con o sin gasto cardíaco bajo y que requieren terapia urgente. Se puede presentar en cardiópatas con fracción de expulsión normal o disminuida, es decir, insuficiencia cardíaca diastólica y sistólica respectivamente. La insuficiencia cardíaca aguda puede dividirse en tres entidades clínicas:

REFERENCIAS (EN ESTE ARTÍCULO)

1. KILLIP T, KIMBALL JT: Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.

2. FORRESTER JS, DIAMOND GA, SWAN HJ: Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 1977; 39: 137-145.

3. NOHRIA A TS, FANG JC, LEWIS EF, ET AL: Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003; 41: 1797-1 1804.

4. FONAROW GC, ET AL: ADHERE, Acute Decompensated Heart Failure Registry. JAMA. 2005; 293: 572-580.

5. MUELLER C, ET AL: Inflamación e Insuficiencia Cardíaca Aguda PCR- estudio BASEL. Am Heart J 2006; 151: 845-850.

6. MCCULLOUGH P, NOWAK R, ET AL: B-Type natriuretic peptide and clinical Judgment in Emergency Diagnosis of heart failure: Analysis from breathing not properly (BNP) Multinational Study. Circulation 2002; 106: 416-422.

7. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287(12): 1531-1540.

8. YOUNG J, ABRAHAM W, ET AL: Results of the VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure. Circulation 2000; 102: 2794-2801.

9. SACKNER-BERNSTEIN J, SKOPICKI HA, AARONSON K: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.

10. HORWICH T, PATEL J, ET AL: Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure. Circulation 2003; 108: 833-838.

11. BINANAY C, CALIFF F, ET AL: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294(13): 1625-1633.

12. DORMANS TP, VAN MEYEL JJ, ET AL: Diuretic efficacy high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376-382.

13. BUTLER J, YOUNG JB, ABRAHAM WT, BOURGE RC, ADAMS KF JR, CLARE R, O’CONNOR CH: For the ESCAPE Investigators Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients. J Am Coll Cardiol 2006; 47: 2462-2469.

14. SCROGGINS N, EDWARDS M, ET AL: Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure. Congest Heart Fail 2005; 11(6): 311-314.

15. FOLLATH F, ET AL: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002; 360(9328): 196-202.

16. CUFFE MS, CALIFF RM, ADAMS KF, BOURGE RC, COLUCCI W, MASSIE B, O’CONNOR CM, PINA I, QUIGG R, SILVER M, ROBINSON LA, LEIMBERGER JD, GHEORGHIADE M: Rationale and design of the OPTIME-CHF trial: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure. Am Heart J 2000; 139: 15-22.

17. LEHTONENL: Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure. Curr Heart Fail Rep 2004; 1(3): 136-144. Review.